Kiniksa Pharmaceuticals International (KNSA) Current Leases (2019 - 2026)

Kiniksa Pharmaceuticals International has reported Current Leases for 8 years, with the latest figure at $3.2 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases rose 38.31% year-over-year to $3.2 million; the trailing twelve-month figure through Mar 2026 stood at $3.2 million (up 38.31% YoY), and the FY2025 full-year result was $3.0 million, up 49.87% from the prior year.
• Current Leases for Q1 2026 stood at $3.2 million, up from $3.0 million in the prior quarter.
• The five-year high for Current Leases was $3.5 million in Q1 2023, with the low at $2.0 million in Q4 2024.
• Historically, Current Leases has averaged $2.7 million across 5 years, with a median of $2.5 million in 2025.
• Annual changes were most pronounced in 2024 — Current Leases tumbled 34.55% — and 2025, when it soared 49.87%.
• Kiniksa Pharmaceuticals International's Current Leases stood at $3.3 million in 2022, then slumped by 31.75% to $2.3 million in 2023, then decreased by 11.54% to $2.0 million in 2024, then surged by 49.87% to $3.0 million in 2025, then gained by 6.13% to $3.2 million in 2026.
• The last three Current Leases figures came in at $3.2 million (Q1 2026), $3.0 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.